Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 193Carcinoma, Non-Small-Cell Lung 160Ovarian Neoplasms 96Lung Neoplasms 58Fallopian Tube Neoplasms 57Neoplasms 50Triple Negative Breast Neoplasms 36Neoplasm Metastasis 36Esophageal Neoplasms 22Carcinoma, Ovarian Epithelial 22Parkinson Disease 4, Autosomal Dominant Lewy Body 21Stomach Neoplasms 20Squamous Cell Carcinoma of Head and Neck 20Head and Neck Neoplasms 19Endometrial Neoplasms 19Adenocarcinoma of Lung 17Melanoma 15Breast Neoplasms, Male 15Urinary Bladder Neoplasms 13Carcinoma 12Uterine Cervical Neoplasms 11Recurrence 11Carcinoma, Squamous Cell 11Brenner Tumor 11Adenocarcinoma Of Esophagus 10Small Cell Lung Carcinoma 9Peritoneal Neoplasms 9Esophageal Squamous Cell Carcinoma 9Adenocarcinoma, Bronchiolo-Alveolar 9Prostatic Neoplasms 8

Interventions

spartalizumab 1STA 9090 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Disorders of Sex Development × Paclitaxel × Clear all
NCT02012192 2019-08-13

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Medical University Innsbruck

Phase 1/2 Terminated
133 enrolled 10 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡